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 CURRENTOPINION Targeting angiotensinogen with RNA-based
therapeutics
Liwei Rena,b, Katrina M. Mirabito Colafellac, Dominique M. Bove´ea,
Estrellita Uijla, and A.H. Jan Dansera
Purpose of review
To summarize all available data on targeting angiotensinogen with RNA-based therapeutics as a new tool
to combat cardiovascular diseases.
Recent findings
Liver-targeted, stable antisense oligonucleotides and small interfering RNA targeting angiotensinogen are
now available, and may allow treatment with at most a few injections per year, thereby improving
adherence. Promising results have been obtained in hypertensive animal models, as well as in rodent
models of atherosclerosis, polycystic kidney disease and pulmonary fibrosis. The next step will be to
evaluate the optimal degree of suppression, synergy with existing renin–angiotensin–aldosterone system
blockers, and to determine harmful effects of suppressing angiotensinogen in the context of common
comorbidities, such as heart failure and chronic kidney disease.
Summary
Targeting angiotensinogen with RNA-based therapeutics is a promising new tool to treat hypertension and
diseases beyond. Their long-lasting effects are particularly exciting, and if translated to a clinical
application of at most a few administrations per year, may help to eliminate nonadherence.
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INTRODUCTION
Although more than 100 commercial drugs and
drug combinations are available for the treatment
of hypertension, a substantial proportion of the
hypertensive population remains uncontrolled or
suboptimally controlled. This could relate to non-
adherence and/or drug ineffectiveness. The latter
might be because of counterregulatory mecha-
nisms (like a rise in renin [1]) that eliminate or
diminish the initial blood pressure-lowering effect.
Hence, given the deleterious consequences of
uncontrolled blood pressure, there still is a need
for novel treatment options that preferably are not
counterbalanced by the upregulation of contractile
mechanisms and circumvent nonadherence. An
attractive option is targeting angiotensinogen
(AGT) with RNA-based therapeutics. As all angio-
tensins stem from AGT, deleting AGT will suppress
angiotensin (Ang) formation, even when renin
levels rise. Furthermore, the dosing frequency with
this approach might go down to a few times per
year, thereby potentially reducing the clinical and
economic burden of nonadherence.
RNA THERAPEUTIC APPROACHES
RNA-based therapies bind to RNA and change the
expression of any protein, even those not amenable
to traditional approaches involving small-molecule
drugs. A number of RNA therapeutic approaches
have been developed [2
&&
,3
&&
], with antisense oligo-
nucleotides (ASO) that inhibit RNA translation and
oligonucleotides that function via the RNA interfer-
ence (RNAi) pathway being the most clinically rele-
vant. ASO-based therapies utilize Watson–Crick’s
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base-pairing rules and single-stranded DNA contain-
ing 15–30 nucleotides, which are designed in anti-
sense orientation to the premRNA and mRNA of
interest. Mature mRNA is formed in the nucleus
by splicing the introns of premRNA. ASOs are able
to modulate alternative splicing by binding to the
premRNA producing different protein variants and
changing the prevalence of one variant. When ASOs
bind to their target mRNA, RNase H1 cleaves the
RNA in an RNA–DNA duplex in both the cytoplasm
and nucleus [4] destroying themRNA and inhibiting
the translation of the target protein (Fig. 1a). Chem-
ically modified ASOs with phosphorothioate link-
ages can trigger RNA cleavage even in the absence of
transfection reagent [5,6]. In contrast to the ASO
approach, RNAi-based therapies utilize double-
stranded RNA and exploit the RNAi process, an
evolutionary conserved mechanism for the regula-
tion of gene expression. At present, the majority of
RNAi-based therapies employ noncoding small
interfering RNA (siRNA) that are 21–23 bases in
length and work naturally in the cell as a part of
KEY POINTS
 Liver-targeted, stable antisense oligonucleotides and
small interfering RNA-targeting angiotensinogen,
capable of suppressing angiotensinogen in a dose-
dependent manner, are now available.
 Suppressing angiotensinogen exerts similar effects as
classical blockers of the renin–angiotensin–aldosterone
system (RAAS) in hypertensive animal models, as well
as in rodent models for atherosclerosis, polycystic
kidney disease and pulmonary fibrosis.
 Future studies should evaluate their safety, for example,
in the context of common comorbidities, such as heart
failure and chronic kidney disease, and synergy with
existing RAAS blockers.
 The long-lasting effects of this approach are particularly
exciting, and if translated to a clinical application of at
most a few administrations per year, may help to
eliminate nonadherence.
FIGURE 1. Inhibition of RNA translation by (a) antisense oligonucleotide or (b) RNA interference. See text for further
explanation. Ago-2, argonaute-2; ASGPR, asialoglycoprotein receptor; RISC, RNA-Induced Silencing Complex.
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the RNA-Induced Silencing Complex (RISC). Unlike
ASOs, when siRNA enters the cell it stays inactive
until loadedby transactivation responsiveRNA-bind-
ing protein into Argonaute where the passenger
strand is removedand the remainingantisense strand
binds complementary mRNA targets, leaving Argo-
naute endoribonuclease to cleave the mRNA, thus
preventing protein translation [7] (Fig. 1b). In mam-
mals, Argonaute contains an RNase H domain, but
cleaves RNA in anRNA–RNAduplex [8]. Themajority
of RNA-based therapies in clinical pipeline utilize the
RNAi approach (Table 1). This is unsurprising given
that a major advantage of RNAi over ASO for thera-
peutic applications is that RNAi ismuchmore potent
and has a longer inhibitory effect [9].
The clinical translation of RNAi-based therapies
has faced a number of challenges including off-target
effects, siRNA delivery, immune reactions and toxic-
ity [2
&&
]. The biggest hurdle has been delivery
as siRNAs do not readily cross the cell membrane.
Various approaches have been proposed to solve the
problem of siRNA delivery in vivo, for example,
viruses, cationic lipids, polymers, and nanoparticles
[10,11]. One of the most promising approaches to
Table 1. RNA-based therapies currently in clinical development
Disease target
Pharmaceutical
company
Drug (alternate
name)
Therapeutic
approach
Stage of
development
Cancer
Blood cancers
miR-155 miRagen Cobomarsen
(MRG-106)
RNAi
(miRNA)
Phase 1/2
Clear cell renal cell carcinoma
HIF-2a Arrowhead ARO-HIF2 RNAi (siRNA) Pre-IND
Cholangiocarcinoma
TGF-b1 and COX2 Sirnaomics STP705L RNAi (siRNA) Phase 1
Nonmelanoma skin cancer
TGF-b1 and COX2 Sirnaomics STP705 RNAi (siRNA) Phase 2
Pancreatic cancer
KRAS G12D Silenseed KRAS-LODER RNAi (siRNA) Phase 2 [23]
Prostate cancer
Androgen receptors Ionis ARRx (IONIS-AR-
2.5Rx)
ASO Phase 1/2
Various cancers
STAT3 Ionis-AstraZeneca Danvatirsen
(ISIS481464)
ASO Phase 1/2
Cardiometabolic
Clotting disorders
Hepatic Factor XI Ionis-Bayer IONIS-FXIRx ASO Phase 2 [24]
Ionis-Bayer IONIS-FXI-LRx ASO Phase 1
Dyslipidemias
Hepatic PCSK9 Alnylam- The
Medicines
Company
Inclisiran (ALN-
PCSSC)
RNAi (siRNA) Phase 3
[16,25–28]
Hepatic Apo C-III Arrowhead ARO-APOC3 RNAi (siRNA) Phase 1
Ionis-Akcea/
Novartis
AKCEA-APOCIII-LRx ASO Phase 2
Ionis-Akcea Waylivra
(Volanesorsen)
ASO Phase 3
[29–35]
Hepatic ANGPTL3 Arrowhead ARO-ANG3 RNAi (siRNA) Phase 1
Ionis-Akcea AKCEA-ANGPTL3-LRx ASO Phase 2
Hepatic Apo A Arrowhead-Amgen AMG 890 RNAi (siRNA) Phase 1
Ionis-Akcea/
Novartis
AKCEA-APO(a)-LRx ASO Phase [36]
Silence Therapeutics SLN360 IND/CTA due
in 2020
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Table 1 (Continued )
Disease target
Pharmaceutical
company
Drug (alternate
name)
Therapeutic
approach
Stage of
development
Undisclosed target Ionis-AstraZeneca AZD8233 (IONIS-
AZ4–2.5LRx)
ASO Phase 1
Hypertension
Hepatic AGT Alnylam ALN-AGT RNAi (siRNA) Phase 1
Ionis IONIS-AGT-LRx ASO Phase 2
Ischemia
miR-92a miRagen-Servier MRG-110 RNAi
(miRNA)
Phase 1
Type 2 diabetes
Hepatic glucagon receptors Ionis IONIS-GCGR(Rx) ASO Phase 2 [37]
Endocrine disorders
Acromegaly
Growth hormone receptor Ionis IONIS-GHR-LRx ASO Phase 2
Fibrosis
Hypertrophic scar reduction
TGF-b1 and COX2 Sirnaomics STP705L RNAi (siRNA) Phase 2
Cutaneous fibrosis
miR-29 miRagen Remlarsen (MRG-201) RNAi
(miRNA)
Phase 2
Genetic
b-Thalassemia
Hepatic TMPRSS6 Ionis IONIS-TMPRSS6-LRx ASO Phase 2
Silence Therapeutics SLN124 RNAi (siRNA) CTA approved
Complement-mediated diseases
Hepatic C5 Alnylam Cemdisiran (ALN-
CC5)
RNAi (siRNA) Phase 2
Alnylam-Regeneron Cemdisiran/
Pozelimab Combo
RNAi (siRNA) Phase 1/2
Hepatic complement factor B Ionis-Roche IONIS-FB-LRx ASO Phase 2
Cystic fibrosis
Pulmonary aENaC Arrowhead ARO-ENaC RNAi (siRNA) Pre-IND
Ionis IONIS-ENAC-2.5Rx ASO Phase 2
Hemophilia and are bleeding disorders
Hepatic antithrombin Alnylam- Sanofi
Genzyme
Fitusiran (ALN-AT3) RNAi (siRNA) Phase 3
Hereditary angioedema
Prekallikrein Ionis IONIS-PKK-LRx ASO Phase 2
Primary hyperoxaluria
Hepatic glycolate oxidase type 1 Alnylam Lumasiran (ALN-GO1) RNAi (siRNA) Phase 3
Dicerna DCR-PHXC RNAi (siRNA) Phase 1
Transthyretin-mediated (ATTR) amyloidosis
Hepatic transthyretin Alnylam Vutrisiran (ALN-
TTRsc02)
RNAi (siRNA) Phase 3
Ionis-Akcea AKCEA-TTR-LRx ASO Phase 1
Kidney diseases
Delayed graft function
Pro-apoptotic gene p53 Quark QRK306 (QPI-1002) RNAi (siRNA) Phase 3
AKI following cardiac surgery
Pro-apoptotic gene p53 Quark QRK209 (QPI-1002) RNAi (siRNA) Phase 2
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improve the delivery and safety of siRNA is biocon-
jugation, the covalent connection of siRNAs with
biogenic molecules, such as lipophilic molecules,
antibodies, aptamers, ligands, peptides, or polymers,
which also cause less immunoreaction [12,13]. The
development of trivalent N-acetylgalactosamine
(GalNAc)–siRNA conjugates for targeted delivery of
siRNA to the liver is the most successful. GalNAc
binds to theasialoglycoprotein receptor that ishighly
expressed on hepatocytes resulting in rapid endocy-
tosis [14]. The GalNAc approach has also been
employed to enhance ASO delivery to hepatocytes
by 10-fold versus free ASOs in preclinical models,
resulting in a significant dose reduction [15]. In a
phase 2 clinical trial, hepatocyte-directed GalNAc–
siRNAmolecules have been shown toyield incredible
Table 1 (Continued )
Disease target
Pharmaceutical
company
Drug (alternate
name)
Therapeutic
approach
Stage of
development
LIVER DISORDERS
AATD-associated liver disease
Hepatic mutant AAT Arrowhead ARO-AAT RNAi (siRNA) Phase 2
Alnylam ALN-AAT02 RNAi (siRNA) Phase 1/2
Dicerna DCR-A1AT RNAi (siRNA) Pre-IND
Acute hepatic porphyria
Hepatic ALAS1 Alnylam Givosiran (ALN-AS1) RNAi (siRNA) Phase 3 [38]
ARLD/NAFLD
HSD17B13 Arrowhead ARO-HSD RNAi (siRNA) Pre-IND
HBV
HBV gene products Arrowhead- Janssen JNJ-3989 (ARO-HBV) RNAi (siRNA) Phase 2
Arbutus AB-729 RNAi (siRNA) Phase 1
Alnylam VIR-2218 (ALN-
HBV02)
RNAi (siRNA) Phase 1/2
Ionis-GSK IONIS-HBV-LRx ASO Phase 2
Ionis-GSK IONIS-HBVRx ASO Phase 2
Dicerna DCR-HBVS RNAi (siRNA) Phase 1
Neurological disorders
Huntington’s disease
Huntingtin protein Ionis-Roche IONIS-HTTRx ASO Phase 3 [39]
Amyotrophic lateral sclerosis
SOD1 Ionis-Biogen Tofersen (BIIB067) ASO Phase 3 [40]
Mutated CORF72 gene Ionis-Biogen IONIS-C9Rx (BIIB078) ASO Phase 2
Alzheimer’s disease and
frontotemporal degeneration
MAPT Ionis-Biogen IONIS-MAPTRx
(BIIB080)
ASO Phase 2
Centronuclear myopathy
Dynamin 2 protein Ionis-Dynacure IONIS-DNM2–2.5Rx ASO Phase 1
Ocular disorders
Dry eye syndrome
TRPV1 Sylentis Tivanisiran (SYL1001) RNAi (siRNA) Phase 3
Glaucoma
b-adrenergic receptor 2 Sylentis Bamosiran
(SLY040012)
RNAi (siRNA) Phase 2
[41,42]
aENaC, epithelial sodium Channel alpha subunit; AAT, Alpha-1 antitrypsin; AATD, Alpha-1 antitrypsin deficiency; AGT, angiotensinogen; AKI, acute kidney
injury; ALAS1, aminolevulinic acid synthase 1; ANGPTL3, angiopoietin-like protein 3; Apo A, apolipoprotein A; Apo C-III, apolipoprotein C-III; ARLD/NAFLD,
Alcohol-related liver disease and nonalcoholic fatty liver disease; ASO, antisense oligonucleotide; C5, complement component 5; CORF72, chromosome 9 open
reading frame 72; CTA, clinical trial authorization; HBV, hepatitis B virus; HIF-2a, hypoxia inducible factor 2a; HSD17B13, 17b-Hydroxysteroid dehydrogenase
type 13; IND, United States Food and Drug Administration investigational new drug application; MAPT, microtubule-associated protein tau; miRNA, microRNA;
PCSK9, proprotein convertase subtilisin kexin type 9; RNAi, RNA interference; siRNA, small interfering RNA; SOD1, superoxide dismutase 1; STAT3, signal
transducer and activator of transcription factor 3; TMPRSS6, Transmembrane protease serine 6; TRPV1, Transient receptor potential vanilloid-1.
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results with stable suppression of proprotein conver-
tase subtilisin/kexin type 9 (PCSK9) achieved for at
least 6 months [16]. RNA-based therapies will not
only fundamentally change thewaywe treatdiseases,
but may also provide treatments for diseases with
unmet clinical need. This has led to RNA-based ther-
apeutics becomingoneof themost rapidly advancing
fields in drug discovery.
CURRENT APPLICATION OF RNA-BASED
THERAPIES
To date, four ASOs and one siRNA-based therapy
have been approved for clinical use. Fomivirsen, an
intravitreally injected inhibition ASO indicated for
the treatment of ocular cytomegalovirus retinitis
(CMV) in acquired immunodeficiency syndrome
(AIDS) individuals, was the first ever RNA-based
therapy to be approved by the US Food and Drug
Administration (FDA) in 1998 and by the European
Medical Association (EMA) in 1999 [17]. However,
in the early 2000s, fomivirsen was withdrawn
from the market as the introduction of highly
active antiretroviral therapy (HAART) dramatically
reduced the number of cases of CMV. A second
inhibition ASO, mipomersen, which is injected sub-
cutaneously and targets mRNA encoding apolipo-
protein B for the treatment of homozygous familial
hypercholesterolemia, was approved for clinical use
in 2014 [18]. Two splice-modulating ASOs, nusi-
nersen for the treatment of spinal muscular atrophy
(2017) [19,20] and eteplirsen for the treatment of
Duchenne muscular dystrophy (2016) [21], are also
approved for clinical use. In 2018, patisiran, an
siRNA encapsulated in a lipid nanoparticle for deliv-
ery to hepatocytes, became the first globally (FDA
and EMA)-approved RNAi therapeutic. Patisiran is
indicated for the treatment of hereditary transthyr-
etin-mediated amyloidosis (hATTR) in adults [22].
In addition, more than 50 RNA-based therapies
for diseases as varied as cancer, neurodegenerative
disease and cardiovascular disease are currently in
clinical development with several investigational
new drug and clinical trial applications expected
to be filed within the next 2 years (Table 1). Inter-
estingly, a number of ASO and RNAi therapies
are being developed for the same disease targets
(Table 1), including hepatic AGT for the treatment
of hypertension, which are in phase 2 and phase 1,
respectively.
ANGIOTENSINOGEN RNA-BASED
THERAPY IN HYPERTENSION
As AGT is the sole precursor of the potent vasocon-
strictor Ang II, it is a promising target for gene
silencing. At present, inhibition of the renin–Ang–
aldosterone system (RAAS) is the mainstay for the
treatment of hypertension, heart failure and chronic
kidney disease [43,44]. Yet, the long-term manage-
ment of these conditions remains complicated by
RAAS escape phenomena, during which a counter-
regulatory rise in plasma renin often restores Ang II to
its original pretreatment values [45–47]. As a conse-
quence, blood pressure control commonly requires
multiple antihypertensive drugs, but is impeded by a
decline in therapy adherence with every drug added
to the treatment regimen [48,49].
The clinical need for an antihypertensive thera-
peutic, which prevents Ang reactivation has long
been recognized and may be achieved by blocking
the RAAS at the AGT level. As opposed to classical
RAAS inhibitors, a compensatory rise in renin could
even potentiate blood pressure lowering as it would
facilitate depletion of the remaining AGT (Fig. 2a).
This can be explained as follows. Normally, AGT is
present at levels that exceed Ang levels by many
orders of magnitude. Under such conditions, block-
ing renin, Ang I-converting enzyme (ACE) or the Ang
receptor results in a renin rise,whicheither (partially)
restores Ang II, or increases Ang II above its original
level (in order to overcome blockade of its receptor).
This is easily achievable, simply because there is
ample AGT around to allow this. Even a 100-fold rise
in Ang I generation (sufficient to overcome 99%
renin inhibition!) is feasible. Yet, if the renin rises
are substantial, it is possible that at a certainmoment,
AGT levels start to decrease. During AGT suppression
by RNA-based therapy, AGT levels are down already,
andnowa rise in reninmight be sufficient to result in
complete AGT depletion, particularly when simulta-
neously introducing other types of RAAS blockade,
which induce further rises in renin. Restoration of
Ang II levels is then no longer possible.
Although initial ASO constructs targeting Agt
lowered circulating AGT, Ang II and blood pressure
in parallel in spontaneously hypertensive rats, these
methods lacked potency and specificity: AGT levels
were halved at most, and the effects were short-lived
(<1 week) [51–53]. Similar problems also impeded
the use of Agt-directed siRNA. The introduction of
lipid nanoparticle delivery enhanced AGT downre-
gulation, although stable suppression still necessi-
tated weekly intravenous dosing [54]. Additionally,
treatment with lipid delivery vehicles causes an
inflammatory response, andmust therefore, be given
with histamine receptor antagonists, nonsteroidal
anti-inflammatory drugs and relatively high doses
of glucocorticoids [55].
Conjugating GalNAc to ASO and RNAi molecules
enabled general therapeutic application. Subsequent
selective accumulation in the liver permittedminimal
Targeting angiotensinogen with RNA-based therapeutics Ren et al.
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FIGURE 2. Near elimination of angiotensinogen is required for lowering of Ang II. (a) Inhibition of the renin–angiotensin–
aldosterone system (RAAS) at the angiotensinogen (AGT) level may prevent RAAS reactivation, because a rise in plasma renin
levels, because of a lack of negative feedback exerted by angiotensin (Ang) II on renin production, could now facilitate depletion of
remaining AGT. (b) Plasma AGT, (c) active plasma renin concentration (APRC), (d) plasma Ang II, (e) renal Ang II and (f) mean
arterial pressure (MAP) of spontaneously hypertensive rats after 4 weeks of vehicle, valsartan, AGT siRNA or valsartan with siRNA
treatment (all groups n¼8). Data, modified from Uijl et al. [50&&], are represented as means  SEM and analyzed using two-way
ANOVA and posthoc Bonferroni (MAP) or transformed to natural logarithms before analysis by one-way ANOVA and posthoc
Bonferroni (RAS parameters). P<0.05, P0.001, P0.0001 vs. vehicle or otherwise indicated; #P0.0001.
Pathophysiology of hypertension
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invasive delivery via subcutaneous injection and opti-
mization of AGT downregulation, as circulating AGT
levels are determined by hepatic synthesis [56,57
&
].
Indeed, by improving liver activity eight-fold, Gal-
NAc-conjugation potentiated AGT inhibition of ASOs
to maximally 88% in a dose-dependent manner [58].
Interestingly, a reduction of at least 75%was required
to simultaneously lower blood pressure, which then
remained low for a period of 7–10 days after a single
dose. This relates to the above-mentioned upregula-
tion of renin. In fact, in a study employing GalNAc-
siRNA to target Agt [50
&&
], even when AGT was
decreasedby97.9%,circulatingAng II remainedintact
because of renin upregulation. Only a 99.8% reduc-
tion, achieved by combining siRNA with valsartan
(which furtherupregulates renin, therebyadditionally
lowering AGT), was required to deplete both systemic
and renal Ang II (Fig. 2b–e). The latter observation
implies that renal Ang generation relies on AGT of
hepatic origin. Consequently, AGT siRNA monother-
apy provided similar antihypertensive and cardiopro-
tective efficacy as conventional RAAS inhibition,
whereas near elimination of AGT by addition of val-
sartanyieldedasynergistic reduction inbloodpressure
and cardiac hypertrophy, without adversely affecting
renal function (Fig. 2f). Unique to GalNAc-siRNA is its
long-lasting effectiveness [22], as opposed to an ASO
liver half-life of 2–4 weeks [58]. These findings suggest
that, in clinical practice, AGT inhibition mediated by
RNAimaynotonlypreventRAAS reactivationbut also
improve cardiovascular outcome and therapy adher-
ence because of a sustained and stable single-dose
efficacy lasting weeks to months [50
&&
].
ANGIOTENSINOGEN RNA-BASED
THERAPY IN OTHER DISEASES
Although the potential for clinical translation is
currently being investigated in patients, preclinical
studies now focus on safety and efficacy inmodels of
chronic kidney disease and heart failure. However,
the application of AGT inhibition is not limited to
hypertension and related end-organ damage. Poly-
cystic kidney disease (PKD) appears an especially
promising target, withmultiple recent studies show-
ing beneficial effects in animal models of this dis-
ease [59,60,61
&
]. PKD is caused by mutations in the
Pkd1 and Pkd2 genes. In affected patients, these
mutations lead to early onset hypertension, the
progressive growth of renal cysts and kidney failure.
Conventional treatment with ACE inhibitors or Ang
receptor blockers (ARBs) effectively lowers blood
pressure in PKD, but whether this treatment also
reduces the decline in kidney function is unclear
[62,63]. Experimentally, PKD may be studied in
mice with targeted knockout of the Pkd1 or Pkd2
gene, with both models developing progressive
intrarenal cysts and kidney failure [64,65]. In Pkd2
knockoutmice, treatment with AGT ASO resulted in
a reduction in kidney size, lower total cyst volume
and improved kidney function compared with con-
trol treatment (scrambled ASO) [59]. Pkd1 knockout
mice displayed similar reductions in kidney size and
cyst volume after treatment with AGT ASO [60,61
&
].
Interestingly, in the latter model, the effects of AGT
ASO on cyst growth were independent of changes in
SBP. In contrast, ACE inhibition with lisinopril sig-
nificantly lowered SBP, but did not reduce kidney
size to a similar degree as AGT ASO and had no effect
on cyst volume [60].
Experimental evidence indicates that AGT ASO
may also be effective in the treatment of atheroscle-
rosis. Increased activity of the RAAS promotes ath-
erosclerosis through activation of AT1A receptors
[66–68]. Treatment of spontaneously hypertensive
rats on a diet enriched with high fat and vitamin D3
(i.e. to induce atherosclerosis) withGal-PEG-Et (GPE)
nanoparticles carrying short hairpin RNA (shRNA)
that specifically targets Agt in the liver decreased SBP
and attenuated the development of atherosclerotic
lesions compared with control animals [69]. Similar
effects were observed in another animal model for
atherosclerosis and obesity, that is, LDL receptor
knockout mice fed with a saturated fat-enriched diet
[70]. In thesemice, treatmentwithAGTASO resulted
in decreased blood pressure, less atherosclerosis, and
diminished body weight gain. Correspondingly, pre-
vious clinical studies also showed beneficial effects of
ACE inhibitors and ARBs on the progression of ath-
erosclerotic plaques [71,72]. However, whether AGT
ASO is effective in the treatment of atherosclerosis in
patients has yet to be investigated.
Finally, AGT ASO treatment has been used as a
therapeutic strategy against experimental pulmonary
fibrosis. Currently, treatment options for idiopathic
pulmonary fibrosis are limited, leaving most patients
withapoorprognosis – themedian survival rate is 2–5
years. Several studies in animals (i.e., mice and rats)
with bleomycin-induced lung injury showed thatAng
II contributes to pulmonary fibrosis, whereas treat-
ment with renin inhibitors, ACE inhibitors, and ARBs
attenuates disease progression [73–77]. In this same
animal model, intratracheal administration of AGT
ASO was found to decrease pulmonary AGT concen-
trations and lung fibrosis [78], but no comparisonwas
made to conventional RAAS inhibitors.
CONCLUSION
Targeting AGT with RNA-based therapeutics is a
promising new tool to treat hypertension and dis-
eases beyond, includingheart failure, atherosclerosis,
Targeting angiotensinogen with RNA-based therapeutics Ren et al.
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diabetic nephropathy, polycystic kidney disease and
pulmonary fibrosis. The long-lasting effects of RNA-
based therapeutics are particularly exciting, and if
translated to a clinical application of at most a few
administrations per year,may help to eliminate non-
adherence. To what degree the effects of such thera-
peutics are fully identical to those of other RAAS
blockers (given the fact that they eliminate all Ang
metabolites) remains to be determined. It will also be
important to determine to what level AGT should be
suppressed to induce meaningful effects, and
whether there is a role for AGT synthesized outside
the liver [79]. Synergy in combination with other
RAAS blockers needs to be evaluated, as well as the
potential harmful effects of suppressing AGT in the
context of common comorbidities, such as heart
failure and chronic kidney disease, where AGTmight
already be suppressed.
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